. "Vali\u0161, Martin" . . "Tal\u00E1b, Radom\u00EDr" . . "Neurologie pro praxi" . "Roztrou\u0161en\u00E1 skler\u00F3za mozkom\u00ED\u0161n\u00ED (RSM) je chronick\u00E9 z\u00E1n\u011Btliv\u00E9 onemocn\u011Bn\u00ED centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu, kter\u00E9 vede k\u00A0demyelinizaci nervov\u00FDch vl\u00E1ken a\u00A0jejich p\u0159\u00EDm\u00E9mu po\u0161kozen\u00ED. Je \u0159azena mezi autoimunitn\u00ED onemocn\u011Bn\u00ED. RSM je nej\u010Dast\u011Bj\u0161\u00ED neurologickou p\u0159\u00ED\u010Dinou invalidity u\u00A0mlad\u0161\u00ED a\u00A0st\u0159edn\u00ED v\u011Bkov\u00E9 populace. \u00DAnava pat\u0159\u00ED mezi\u00A0\u010Dast\u00E9 a\u00A0z\u00E1va\u017En\u00E9 klinick\u00E9 p\u0159\u00EDznaky onemocn\u011Bn\u00ED. P\u0159\u00ED\u010Dina patologick\u00E9 \u00FAnavy je nejednotn\u00E1 a\u00A0nejpravd\u011Bpodobn\u011Bj\u0161\u00ED je multifaktori\u00E1ln\u00ED etiologie. Diagnostika \u00FAnavy u\u00A0RSM a\u00A0jej\u00ED kvantifikace je obt\u00ED\u017En\u00E1. K\u00A0ovlivn\u011Bn\u00ED \u00FAnavy vyu\u017E\u00EDv\u00E1me na prvn\u00EDm m\u00EDst\u011B nefarmakologick\u00FDch mo\u017Enost\u00ED l\u00E9\u010Dby nap\u0159\u00EDklad: stanoven\u00ED ekonomick\u00E9ho denn\u00EDho pl\u00E1nu, vy\u0159azen\u00ED aktivit zvy\u0161uj\u00EDc\u00EDch \u00FAnavu, nutri\u010Dn\u00ED podp\u016Frn\u00FD re\u017Eim a\u00A0energii \u0161et\u0159\u00EDc\u00ED re\u017Eim, pravideln\u00E1 aerobn\u00ED z\u00E1t\u011B\u017E. Pokud jsou tyto postupy nedosta\u010Duj\u00EDc\u00ED, p\u0159istoup\u00EDme k\u00A0farmakoterapii. Z\u00A0farmakoterapie pou\u017E\u00EDv\u00E1me v\u00A0prv\u00E9 \u0159ad\u011B amantadin, modafinil a\u00A0jako l\u00E9\u010Dbu druh\u00E9 linie antidepresiva (SSRI), vitaminoterapie B \u0159ady, nootropika."@cs . . . . "40;41" . "\u00DAnava u roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED a mo\u017Enosti jej\u00EDho ovlivn\u011Bn\u00ED v neurologick\u00E9 praxi"@cs . "11150" . "1213-1814" . "Fatigue in multiple sclerosis and possibilities her affecting in neurological practice"@en . . . . . "\u00DAnava u roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED a mo\u017Enosti jej\u00EDho ovlivn\u011Bn\u00ED v neurologick\u00E9 praxi" . "RIV/00216208:11150/05:00004771" . . "\u00DAnava u roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED a mo\u017Enosti jej\u00EDho ovlivn\u011Bn\u00ED v neurologick\u00E9 praxi"@cs . "2"^^ . "[DA6FA0BEFD6B]" . . "Roztrou\u0161en\u00E1 skler\u00F3za mozkom\u00ED\u0161n\u00ED (RSM) je chronick\u00E9 z\u00E1n\u011Btliv\u00E9 onemocn\u011Bn\u00ED centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu, kter\u00E9 vede k\u00A0demyelinizaci nervov\u00FDch vl\u00E1ken a\u00A0jejich p\u0159\u00EDm\u00E9mu po\u0161kozen\u00ED. Je \u0159azena mezi autoimunitn\u00ED onemocn\u011Bn\u00ED. RSM je nej\u010Dast\u011Bj\u0161\u00ED neurologickou p\u0159\u00ED\u010Dinou invalidity u\u00A0mlad\u0161\u00ED a\u00A0st\u0159edn\u00ED v\u011Bkov\u00E9 populace. \u00DAnava pat\u0159\u00ED mezi\u00A0\u010Dast\u00E9 a\u00A0z\u00E1va\u017En\u00E9 klinick\u00E9 p\u0159\u00EDznaky onemocn\u011Bn\u00ED. P\u0159\u00ED\u010Dina patologick\u00E9 \u00FAnavy je nejednotn\u00E1 a\u00A0nejpravd\u011Bpodobn\u011Bj\u0161\u00ED je multifaktori\u00E1ln\u00ED etiologie. Diagnostika \u00FAnavy u\u00A0RSM a\u00A0jej\u00ED kvantifikace je obt\u00ED\u017En\u00E1. K\u00A0ovlivn\u011Bn\u00ED \u00FAnavy vyu\u017E\u00EDv\u00E1me na prvn\u00EDm m\u00EDst\u011B nefarmakologick\u00FDch mo\u017Enost\u00ED l\u00E9\u010Dby nap\u0159\u00EDklad: stanoven\u00ED ekonomick\u00E9ho denn\u00EDho pl\u00E1nu, vy\u0159azen\u00ED aktivit zvy\u0161uj\u00EDc\u00EDch \u00FAnavu, nutri\u010Dn\u00ED podp\u016Frn\u00FD re\u017Eim a\u00A0energii \u0161et\u0159\u00EDc\u00ED re\u017Eim, pravideln\u00E1 aerobn\u00ED z\u00E1t\u011B\u017E. Pokud jsou tyto postupy nedosta\u010Duj\u00EDc\u00ED, p\u0159istoup\u00EDme k\u00A0farmakoterapii. Z\u00A0farmakoterapie pou\u017E\u00EDv\u00E1me v\u00A0prv\u00E9 \u0159ad\u011B amantadin, modafinil a\u00A0jako l\u00E9\u010Dbu druh\u00E9 linie antidepresiva (SSRI), vitaminoterapie B \u0159ady, nootropika." . "Fatigue; multiple; sclerosis; possibilities; affecting; neurological; practice"@en . . "Fatigue in multiple sclerosis and possibilities her affecting in neurological practice"@en . . "CZ - \u010Cesk\u00E1 republika" . "2"^^ . "Cerebrospinal multiple sclerosis is a chronic inflammatory disease of the central nervous system that leads to demyelinization of neural fibres and their damage. It is classified as an autoimmune disease.It is the most frequent neurologic cause of disability in young and middle aged people. Fatigue belongs to its frequent and severe clinical signs. The cause of the pathological tiredness is not homogenous, the most probable cause being multifactorial etiology.The diagnosis of the tiredness due to multiple cerebrospinal sclerosis, especially its quantification, is difficult. First of all, some non-pharmacological means are used to reduce the tiredness, such as setting an economic daily routine plan, reduction of tiring activities, nutrition supportive and energy saving management, and regular aerobic strain. If these methods prove to be insufficient, pharmacological therapy is started primarily with amantadine and/or modafinil followed by antidepressants (SSRI), B- vitamin therapy and nootropics."@en . "\u00DAnava u roztrou\u0161en\u00E9 skler\u00F3zy mozkom\u00ED\u0161n\u00ED a mo\u017Enosti jej\u00EDho ovlivn\u011Bn\u00ED v neurologick\u00E9 praxi" . "547808" . "1" . . "RIV/00216208:11150/05:00004771!RIV08-MSM-11150___" . . . "6" . . . "3"^^ . "S" .